Browsing Radiotherapy and Imaging by author "Tree, Alison"
Now showing items 1-7 of 7
-
Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About.
Brand, DH; Tree, AC (Elsevier BV, 2022-07-14) -
Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About.
Brand, DH; Tree, AC (Elsevier BV, 2022-07-14) -
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser, E; Jereczek-Fossa, BA; Pasquier, D; Zilli, T; Van As, N; et al. (2019-12)Background Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still ... -
MRI-guided prostate adaptive radiotherapy - A systematic review.
McPartlin, AJ; Li, XA; Kershaw, LE; Heide, U; Kerkmeijer, L; et al. (2016-06)Dose escalated radiotherapy improves outcomes for men with prostate cancer. A plateau for benefit from dose escalation using EBRT may not have been reached for some patients with higher risk disease. The use of increasingly ... -
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Ost, P; Jereczek-Fossa, BA; Van As, N; Zilli, T; Tree, A; et al.Aims To report the relapse pattern of stereotactic body radiotherapy (SBRT) for oligorecurrent nodal prostate cancer (PCa).Materials and methods PCa patients with ≤3 lymph nodes (N1/M1a) at the time of recurrence were ... -
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.
Jereczek-Fossa, BA; Marvaso, G; Zaffaroni, M; Gugliandolo, SG; Zerini, D; et al.<h4>Background and purpose</h4>Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body ... -
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Hanna, GG; Murray, L; Patel, R; Jain, S; Aitken, KL; et al. (2018-01)Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management ...